FDA Clears Generic Vyvanse as ADHD Medication Shortage Continues


- Advertisement -

The U.S. Food and Drug Administration (FDA) has cleared more than a dozen drug companies to start selling generic versions of the attention deficit hyperactivity disorder (ADHD) medication Vyvanse, a move that may ease an acute shortage of ADHD medicines.

“This is great news for patients who have been struggling to access their medications due to shortages,” says Jack Turban, MD, an assistant professor of child and adolescent psychiatry and the director of the gender psychiatry program at the University of California in San Francisco. “I suspect and hope this will make a substantial impact.”

Multiple ADHD Drugs Are in Short Supply

ADHD medicines have been hard to get for nearly a year now. The FDA first reported shortages for the ADHD medicine Adderall in October 2022. As patients scrambled to find alternatives, other ADHD drugs became scarce, too. In July, the FDA announced shortages of the ADHD drugs Concerta and Vyvanse.

Now the FDA has approved generic versions of Vyvanse, which all include the same active ingredient as the brand-name drug, to be manufactured by a total of 14 different companies. Regulators cleared both capsules and chewable tablets for people 6 years and older with ADHD and for adults with moderate to severe binge eating disorder, another condition treated with Vyvanse.

- Advertisement -


Please enter your comment!
Please enter your name here

Share post:



More like this

White House accuses Republicans of trying to turn border crisis into 'political stunt'

White House press secretary Karine Jean-Pierre is accusing...

Alice Shalvi, Hailed as a Mother of Feminism in Israel, Dies at 96

Alice Hildegard Margulies was born on Oct. 16,...

A Heavy Week Of Economic Data Lies Ahead

Key Takeaways Markets Closed 3Q In The Red ...

No posts to display